OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
Enabling a new era in minimally invasive obesity treatment across Europe
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Relmada expects to initiate its Phase 3 program in the first half of 2026
Subscribe To Our Newsletter & Stay Updated
